Related Experiment Video
Updated: Jun 24, 2025
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba1, Mark L Hartman1, Eric J Lawitz1
1From the Metabolic Dysfunction-Associated Steatotic Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla (R.L.), and Pacific Rim Pathology, San Diego (C.B.) - both in California; Eli Lilly (M.L.H., Y.T., B.B., D.A.R., A.N., M.C.B., A.H.), the Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine (R.V.), and the Department of Pathology and Laboratory Medicine, Indiana University (O.W.C.) - all in Indianapolis; the Texas Liver Institute, University of Texas Health, San Antonio (E.J.L.); the Department of Hepato-Gastroenterology and Digestive Oncology, Angers University Hospital, and Hemodynamics, Interaction of Fibrosis and Hepatic Tumor Invasiveness Laboratory, Structure Fédérative de Recherche Interactions Cellulaires et Applications Thérapeutiques 4208, Angers University - both in Angers, France (J.B.); the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); the Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan (M.Y.); and the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health and Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.).
Tirzepatide significantly improved metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in a phase 2 trial. Further research is needed to confirm tirzepatide
Area of Science:
- Hepatology
- Clinical Trials
- Pharmacology
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) is a severe liver condition with significant mortality risk.
- The efficacy of tirzepatide, a dual GIP/GLP-1 receptor agonist, for MASH with moderate to severe fibrosis remains under investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of tirzepatide in patients diagnosed with MASH and stage F2 or F3 liver fibrosis.
- To determine optimal tirzepatide dosage for MASH treatment.
Main Methods:
- A 52-week, double-blind, randomized, placebo-controlled, multicenter phase 2 trial.
- Participants received weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo.
- Primary endpoint: MASH resolution without fibrosis worsening; Secondary endpoint: Fibrosis improvement by at least one stage.
Main Results:
- Tirzepatide demonstrated superior MASH resolution rates compared to placebo across all tested doses (44-62% vs. 10%).
- Significant fibrosis improvement was observed in tirzepatide groups (51-55%) versus placebo (30%).
- Gastrointestinal events were the most frequent adverse events, generally mild to moderate.
Conclusions:
- Tirzepatide treatment for 52 weeks effectively resolves MASH without worsening fibrosis in patients with moderate to severe liver fibrosis.
- Larger, longer-term studies are warranted to fully establish tirzepatide's efficacy and safety profile for MASH treatment.
More Related Videos
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:23Dipeptidyl Peptidase 4 Inhibitors
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...